Clinical Trial Update: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing maintenance aromatase inhibitors with and without everolimus in hormone receptor-positive metastatic breast cancer; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Metastasis

Drugs mentioned

• Aromatase inhibitors (aromatase inhibitor)
• Everolimus (everolimus)

Snippet

Sponsor: Istituto Oncologico Veneto IRCCS | Conditions: Breast Cancer Metastatic | Phase 3 | Status: COMPLETED